Vir Biotech Shares Rise on Positive Data for Cancer Treatments
Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage biopharmaceutical company said VIR-5818 targets HER2-expressing solid tumors,
Hosted on MSN1h
Morgan Stanley Upgrades Vir Biotechnology (VIR)Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal ...
The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by ...
The industry continues to face financial and regulatory headwinds, including high interest rates and uncertainty about ...
Upstream's breeding technologies, which protect plants from yield-threatening diseases, have already delivered strong results ...
Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its ...
Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...
Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target ...
Prime Minister Narendra Modi said on Thursday that the combination of biotechnology and biomass is an important part of the ...
Nvidia shares rise after falling sharply in the previous session, Palantir stock extends declines, and quantum-computing ...
BofA lowered the firm’s price target on Sana Biotechnology (SANA) to $7 from $8 and keeps a Buy rating on the shares. While political and rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback